--- title: "Progress Highlights: Phase II/III Immunotherapy Trial for Advanced Liver Cancer" description: It is essential to lay a strong foundation during the start-up phase, which involves conducting the necessary background work from subject recruitment to site selection, as this will affect the trial’s outcome. However, if not carried out effectively, this phase of the trial can be delayed, costing time and money to all parties involved. In […] image: https://clinixir.com/hubfs/Edited%20Photos/Clinix_Home_01.png --- [![CLX\_Logo-White](https://clinixir.com/hs-fs/hubfs/Logo/CLX_Logo-White.png?width=193&height=40&name=CLX_Logo-White.png "CLX_Logo-White")](https://clinixir.com) [![CLX\_Logo-Default](https://clinixir.com/hs-fs/hubfs/Logo/CLX_Logo-Default.png?width=169&height=35&name=CLX_Logo-Default.png "CLX_Logo-Default")](https://clinixir.com/) - [Services](https://clinixir.com/services) - [Clinical Trial Management](https://clinixir.com/services/clinical-trail) - [Regulatory Affairs](https://clinixir.com/services/regulatory-affairs) - [Sponsor’s Local Representative & IOR Services](https://clinixir.com/services/sponsor-local-representative-ior) - [Pharmacovigilance](https://clinixir.com/services/pharmacovigilance) - [Biometrics](https://clinixir.com/services/biometrics) - [Site Management Organization](https://clinixir.com/services/site-management-organization) - [Real World Evidence](https://clinixir.com/services/real-world-evidence) - [Data ConneX](https://clinixir.com/services/dataconnex) - [About Us](https://clinixir.com/about-us) - [Our Partners](https://clinixir.com/about-us#our-partners) - [Our Vision and Mission](https://clinixir.com/about-us#vision) - [Board of Directors](https://clinixir.com/about-us#board) - [Updates](https://clinixir.com/blog) - [Careers](https://clinixir.com/careers) - [Contact Us](https://clinixir.com/contact-us) - [Partner Site Network](https://clinixir.com/contact-us#partner-site) [Email Us](mailto:enquiries@clinixir.com) [Email Us](mailto:enquiries@clinixir.com) [Email Us](mailto:enquiries@clinixir.com) More results - [Services](https://clinixir.com/services) - [Clinical Trial Management](https://clinixir.com/services/clinical-trail) - [Regulatory Affairs](https://clinixir.com/services/regulatory-affairs) - [Sponsor’s Local Representative & IOR Services](https://clinixir.com/services/sponsor-local-representative-ior) - [Pharmacovigilance](https://clinixir.com/services/pharmacovigilance) - [Biometrics](https://clinixir.com/services/biometrics) - [Site Management Organization](https://clinixir.com/services/site-management-organization) - [Real World Evidence](https://clinixir.com/services/real-world-evidence) - [Data ConneX](https://clinixir.com/services/dataconnex) - [About Us](https://clinixir.com/about-us) - [Our Partners](https://clinixir.com/about-us#our-partners) - [Our Vision and Mission](https://clinixir.com/about-us#vision) - [Board of Directors](https://clinixir.com/about-us#board) - [Updates](https://clinixir.com/blog) - [Careers](https://clinixir.com/careers) - [Contact Us](https://clinixir.com/contact-us) - [Partner Site Network](https://clinixir.com/contact-us#partner-site) [Email Us](mailto:enquiries@clinixir.com) [Case Study](https://clinixir.com/blog/tag/case-study) # Progress Highlights: Phase II/III Immunotherapy Trial for Advanced Liver Cancer [![Clinixir](https://clinixir.com/hs-fs/hubfs/Clinixir_logo.png?width=40&height=40&name=Clinixir_logo.png)](https://clinixir.com/blog/author/admin) by Clinixir 2 min read May 26, 2025, 11:14:05 AM ## Introduction and Study Overview Clinixir, Thailand’s leading Contract Research Organization (CRO), is pleased to share progress on a Phase II/III clinical trial investigating a potential immunotherapy for advanced hepatocellular carcinoma. This randomized, controlled study aims to enroll 150 patients across sites in Thailand and Malaysia. Clinixir’s role has focused on activating sites, coordinating patient recruitment, and supporting study milestones, advancing the trial’s success and contributing significantly to its overall progress. With nine clinical sites now active across both countries, enrollment is steadily progressing, with patient enrollment anticipated to conclude by mid-2025. ![Clinix\_Home\_03](https://clinixir.com/hs-fs/hubfs/Image%20Stock/Clinix_Home_03.png?width=2000&height=1125&name=Clinix_Home_03.png) ### Progress Updates Clinixir’s efficiency in site activation and patient recruitment has positioned Thailand as a leading contributor to the trial's progress. All sites were operational in a short timeframe, enabling swift enrollment. The first patient was enrolled and received treatment shortly after site activation, reflecting Clinixir’s dedication to advancing the study according to the planned timeline. Recruitment is on track, with a substantial portion of the target patient enrollment achieved within the first year of the trial. ### Positive Outcomes The study is progressing well, with recruitment and enrollment advancing ahead of initial projections. Clinixir’s team has been instrumental in meeting milestones and ensuring a smooth patient experience. The active engagement and commitment of Principal Investigators (PIs), study sites, and our sponsor have been essential, driving rapid site activation, coordinated recruitment, and significant trial progress. Although specific results are not yet available, the progress thus far indicates a strong foundation for positive future outcomes. ### Why Choose Clinixir? Clinixir’s expertise and operational effectiveness have been instrumental in the trial's success to date. Known for their strong relationships with clinical investigators, adherence to global best practices, and collaborative approach with study partners, Clinixir excels in site management, patient recruitment, and data quality. Key factors distinguishing Clinixir include: #### Efficient Site Activation and Management Rapid setup of all trial sites ensured a quick transition to active recruitment. Efficient Site Activation and Management #### Collaborative Partnerships Clinixir’s close collaboration with PIs, study sites, and the sponsor has been pivotal, enabling swift problem-solving and proactive trial support. Collaborative Partnerships #### Robust Patient Recruitment Strategies Clinixir’s targeted recruitment methods and local expertise led to significant patient enrollment within the trial’s early stages. Robust Patient Recruitment Strategies #### Commitment to High-Quality Data Collection Clinixir’s processes prioritize high standards of data integrity, crucial for reliable trial outcomes. Commitment to High-Quality Data Collection As the study progresses, Clinixir’s focus remains on patient retention, protocol adherence, and timely achievement of trial milestones. This collaborative and proactive approach continues to set high standards for clinical research excellence in Thailand and beyond. ## Progress Update Clinixir’s Phase II/III Immunotherapy Study for Advanced Liver Cancer We’re excited to share that our multinational Phase II/III study in advanced hepatocellular carcinoma continues to make strong progress! As of April 2025, 136 patients have been enrolled—over 90% of the target—across 9 active sites in Thailand and Malaysia. ### Recruitment remains steady and is on track to conclude by mid-2025. - Over 90% enrollment milestone achieved - Ongoing recruitment supported by dedicated PIs & site teams - Seamless collaboration with sponsor and stakeholders Clinixir’s strength in site management and its unwavering focus on quality and efficiency continue to drive the success of this impactful study. We remain committed to accelerating access to innovative immunotherapies in the region.   [Request RFP Form](https://clinixir.com/contact-us/rfp) Share this [Share on X](https://x.com/intent/post?url=https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3&text=Progress%20Highlights:%20Phase%20II/III%20Immunotherapy%20Trial%20for%20Advanced%20Liver%20Cancer) [Share on Facebook](https://www.facebook.com/sharer/sharer.php?u=https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3&t=Progress%20Highlights:%20Phase%20II/III%20Immunotherapy%20Trial%20for%20Advanced%20Liver%20Cancer) [Share on LinkedIn](https://www.linkedin.com/shareArticle?mini=true&url=https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3&t=Progress%20Highlights:%20Phase%20II/III%20Immunotherapy%20Trial%20for%20Advanced%20Liver%20Cancer) Previous story [← Is Your EDC System Future-Proof?](https://clinixir.com/blog/is-your-edc-system-future-proof) Next story [Advancing Healthcare Decision-Making Through Network Meta-Analysis →](https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3-1) ## You May Also Like These Related Stories [Advancing Healthcare Decision-Making Through Network Meta-Analysis](https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3-1) ![](https://clinixir.com/hubfs/Edited%20Photos/Clinix_Blog_03-Thumnail.png) [Case Study](https://clinixir.com/blog/tag/case-study) ### Advancing Healthcare Decision-Making Through Network Meta-Analysis May 30, 2025, 2:38:19 PM 2 min read [The Role of Site Management Organizations (SMOs) in Accelerating Clinical Trials in Thailand](https://clinixir.com/blog/the-role-of-site-management-organizations-smos-in-accelerating-clinical-trials-in-thailand) ![](https://clinixir.com/hubfs/Imported_Blog_Media/The-Role-of-Site-Management-Organizations-SMOs-in-Accelerating-Clinical-Trials-in-Thailand_v2.png) [Research Updates](https://clinixir.com/blog/tag/research-updates) ### The Role of Site Management Organizations (SMOs) in Accelerating Clinical Trials in Thailand May 20, 2025, 1:44:47 PM 4 min read [Is Your EDC System Future-Proof?](https://clinixir.com/blog/is-your-edc-system-future-proof) ![](https://clinixir.com/hubfs/Herobanner/Clinix_Blog_04-Thumnail.png) [Research Updates](https://clinixir.com/blog/tag/research-updates) ### Is Your EDC System Future-Proof? May 23, 2025, 10:21:28 AM 4 min read ![CLX\_Logo-Default](https://clinixir.com/hs-fs/hubfs/Logo/CLX_Logo-Default.png?width=206&height=46&name=CLX_Logo-Default.png) [173/18 Asia Centre Building, 17th Floor S Sathorn Rd, Sathon, Bangkok 10120](https://maps.app.goo.gl/XbLGN49iWPSFS1J67) [Download Our Company Booklet](https://clinixir.com/hubfs/Clinixir%20E-Booklet%20-%2009.10.24%201.pdf)  [enquiries@clinixir.com](mailto:enquiries@clinixir.com) [02-163-6430](tel:%2002-163-6430)   02-163-6432 © Copyright 2026 Clinixir All rights reserved. [Privacy Policy](https://clinixir.com/privacy-policy-clinixir) [![Social 01](https://clinixir.com/hs-fs/hubfs/Social%2001.png?width=318&height=313&name=Social%2001.png)](https://www.linkedin.com/company/clinixir/?originalSubdomain=th) [![Social 02](https://clinixir.com/hs-fs/hubfs/Social%2002.png?width=318&height=313&name=Social%2002.png)](https://www.facebook.com/clinixirthailand/) [![Social 03](https://clinixir.com/hs-fs/hubfs/Social%2003.png?width=318&height=313&name=Social%2003.png)](mailto:enquiries@clinixir.com) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Clinixir", "url" : "https://clinixir.com/blog/author/admin" }, "dateModified" : "2025-05-30T09:55:16.133Z", "datePublished" : "2025-05-26T04:14:05.000Z", "headline" : "Progress Highlights: Phase II/III Immunotherapy Trial for Advanced Liver Cancer", "image" : [ "https://clinixir.com/hubfs/Edited%20Photos/Clinix_Home_01.png" ], "mainEntityOfPage" : { "@id" : "https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://clinixir.com/hubfs/CLX_Logo-Default.png" }, "name" : "Clinixir" } } ```